权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

REGULATION OF HUMAN GLUCOSE HOMEOSTASIS BY THE NOVEL CHC22 CLATHRIN ISOFORM

新型 CHC22 网格蛋白异构体对人体葡萄糖稳态的调节

基本信息

批准号：
MR/S008144/1
负责人：
Frances Martha Brodsky
金额：
$ 74.22万
依托单位：
University College London
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2019
资助国家：
英国
起止时间：
2019 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=MR%2FS008144%2F1
关键词：
REGULATION HUMAN GLUCOSE HOMEOSTASIS NOVEL

项目摘要

Type 2 Diabetes (T2D) and Insulin Resistance (IR), which result in excessively high blood sugar (glucose), generate major health problems affecting 382 million people worldwide and ~6% of the UK population, creating an enormous economic burden on modern society. Development of effective therapies is imperative, and requires fundamental research to identify new therapeutic targets and improve our understanding of human glucose metabolism. This research grant focuses on CHC22 clathrin, a novel regulator of human glucose transport, with potential to influence the health and wellbeing of people living with T2D and IR.Proteins are molecular machines inside cells, and like any machine, a protein must be at the right place at the right time to perform its function properly. Clathrins are proteins responsible for transporting other proteins from one part of the cell to another, a process known as intracellular trafficking. The proposed research investigates a form of clathrin called CHC22 that we have found plays a role in intracellular trafficking of the GLUT4 glucose transporter protein, which regulates blood glucose levels.After a meal, insulin is secreted from the pancreas. In response, glucose is imported from the blood into muscle and fat by GLUT4, a channel through which glucose can pass. During fasting, GLUT4 is held inside cells in the GLUT4 storage compartment (GSC). GLUT4 is released from the GSC to the cell surface in response to insulin produced after feeding, allowing glucose uptake and clearance from blood. In IR, tissues stop releasing GLUT4 and importing glucose in response to insulin, and eventually the pancreas stops secreting insulin (T2D). We have observed that, in muscle from T2D patients, when GLUT4 does not get to the surface after insulin stimulation, GLUT4 is trapped in the GSC together with excessive amounts of our protein of interest, CHC22 clathrin. We hypothesize that the presence of CHC22 at the non-functional GSC contributes to IR.The most familiar role of clathrin is to move proteins from the cell surface to the inside of the cell, known as endocytosis. Multiple molecules of clathrin assemble to form a coat on the inside surface of the cell. The coat pulls the membrane to the inside and eventually the membrane breaks away, forming a coated structure that takes cell-surface proteins with it and carries this cargo to specific intracellular locations. In humans, there are two types of clathrin. Unlike the common CHC17 form, CHC22 is not involved in endocytosis, but has a specialized role in transporting GLUT4 to the GSC. We will characterize this role by analyzing the molecular and cellular properties of CHC22 and how its function is controlled by other proteins. Proposed experiments will define how and where formation of the CHC22 clathrin coat is regulated in cells and characterise CHC22 behaviour changes in response to insulin and and IR. We will also explore the differences between two forms of CHC22 proteins found in humans - differences that may influence the development of IR. Together, these studies will reveal the molecular control of CHC22 function in human glucose regulation.Scientists studying GLUT4 have not yet fully defined properties and regulation of the human GSC, and our experiments will shed light on this fundamental aspect of human nutrition. We will also develop new tools that can be used by other researchers studying IR and T2D. Our studies will further clarify the field of clathrin biology, which has been primarily focused on the roles of CHC17.

2型糖尿病（T2 D）和胰岛素抵抗（IR）导致血糖（葡萄糖）过高，产生影响全球3.82亿人和约6%的英国人口的主要健康问题，对现代社会造成巨大的经济负担。开发有效的治疗方法势在必行，需要基础研究来确定新的治疗靶点，并提高我们对人类葡萄糖代谢的理解。这项研究资助的重点是CHC 22网格蛋白，一种新型的人体葡萄糖转运调节剂，有可能影响T2 D和IR患者的健康和福祉。蛋白质是细胞内的分子机器，像任何机器一样，蛋白质必须在正确的时间处于正确的位置才能正常发挥其功能。网格蛋白是负责将其他蛋白质从细胞的一部分转运到另一部分的蛋白质，这一过程称为细胞内运输。这项拟议中的研究调查了一种名为CHC 22的网格蛋白，我们发现它在GLUT 4葡萄糖转运蛋白的细胞内运输中发挥作用，该蛋白调节血糖水平。作为响应，葡萄糖通过GLUT 4从血液输入到肌肉和脂肪中，GLUT 4是葡萄糖可以通过的通道。在禁食期间，GLUT 4被保存在GLUT 4储存室（GSC）的细胞内。GLUT 4响应于进食后产生的胰岛素从GSC释放到细胞表面，允许葡萄糖摄取和从血液中清除。在IR中，组织停止释放GLUT 4并响应于胰岛素而输入葡萄糖，最终胰腺停止分泌胰岛素（T2 D）。我们已经观察到，在来自T2 D患者的肌肉中，当GLUT 4在胰岛素刺激后没有到达表面时，GLUT 4与过量的我们感兴趣的蛋白质CHC 22网格蛋白一起被捕获在GSC中。我们推测，在非功能性GSC的CHC 22的存在有助于IR。网格蛋白最熟悉的作用是将蛋白质从细胞表面移动到细胞内部，称为内吞作用。网格蛋白的多个分子组装在细胞的内表面上形成一层外壳。外套将膜拉向内部，最终膜破裂，形成一个涂层结构，它将细胞表面蛋白质带到特定的细胞内位置。在人类中，有两种类型的网格蛋白。与常见的CHC 17形式不同，CHC 22不参与内吞作用，但在将GLUT 4转运到GSC中具有特殊作用。我们将通过分析CHC 22的分子和细胞特性以及其功能如何由其他蛋白质控制来表征这种作用。拟议的实验将确定如何以及在哪里形成的CHC 22网格蛋白外壳是调节细胞和cancer CHC 22行为变化响应胰岛素和IR。我们还将探讨在人类中发现的两种形式的CHC 22蛋白质之间的差异-差异可能影响IR的发展。这些研究将揭示CHC 22在人葡萄糖调节中的分子控制功能。研究GLUT 4的科学家尚未完全确定人GSC的性质和调节，我们的实验将揭示人类营养的这一基本方面。我们还将开发可供其他研究IR和T2 D的研究人员使用的新工具。我们的研究将进一步阐明网格蛋白生物学领域，该领域主要集中在CHC 17的作用上。